Dhiti Life Sciences
Dhiti Life Sciences is India’s leading Contract Research Organization specializing in biotechnology, vaccine development, monoclonal antibodies, recombinant proteins, and immunological studies. With state-of-the-art facilities and a team of experienced scientists, the company is committed to advancing healthcare research and providing high-quality experimental services, including Covid-19 related research. They have developed and commercialized a wide range of diagnostic-grade recombinant antigens and monoclonal antibodies, and offer services in small animal studies, gene cloning, protein production, and scientific writing. Their mission is to innovate and collaborate in the field of biotechnology to develop molecules for every drug and drugs for every disease.
Industries
Nr. of Employees
medium (51-250)
Dhiti Life Sciences
B-107, Okhla Industrial Area, Phase - I, New Delhi, India (110020)
Products
Recombinant proteins (research, diagnostic and vaccine candidates)
Recombinant proteins produced for use as vaccine candidates, diagnostic markers, or therapeutic research reagents; available from prokaryotic and eukaryotic platforms with tag-free options.
Monoclonal antibodies (research and diagnostic grade)
Hybridoma-derived monoclonal antibodies developed for biomarker discovery, diagnostic assays and functional binding/inhibition studies; production scalable to gram quantities.
Recombinant proteins (research, diagnostic and vaccine candidates)
Recombinant proteins produced for use as vaccine candidates, diagnostic markers, or therapeutic research reagents; available from prokaryotic and eukaryotic platforms with tag-free options.
Monoclonal antibodies (research and diagnostic grade)
Hybridoma-derived monoclonal antibodies developed for biomarker discovery, diagnostic assays and functional binding/inhibition studies; production scalable to gram quantities.
Services
Immunogenicity testing, toxicology, and related preclinical assays conducted in CPCSEA-approved facilities using mice and rabbits.
End-to-end monoclonal antibody generation including immunization, hybridoma production, high-throughput screening and selection of high-affinity clones.
Design, expression and purification of recombinant proteins using prokaryotic and eukaryotic platforms with option for tag-free production to preserve function.
Computational gene design and codon optimization followed by gene cloning and expression workflows to support protein production.
Advisory services for establishing laboratories, equipment selection, experimental troubleshooting and protocol refinement.
Manuscript preparation, revision, journal formatting, poster and presentation material preparation.
Immunogenicity testing, toxicology, and related preclinical assays conducted in CPCSEA-approved facilities using mice and rabbits.
End-to-end monoclonal antibody generation including immunization, hybridoma production, high-throughput screening and selection of high-affinity clones.
Design, expression and purification of recombinant proteins using prokaryotic and eukaryotic platforms with option for tag-free production to preserve function.
Computational gene design and codon optimization followed by gene cloning and expression workflows to support protein production.
Advisory services for establishing laboratories, equipment selection, experimental troubleshooting and protocol refinement.
Manuscript preparation, revision, journal formatting, poster and presentation material preparation.
Expertise Areas
- Monoclonal antibody development
- Recombinant protein expression and purification
- Gene design and molecular cloning
- In vivo preclinical study execution
Key Technologies
- Hybridoma-based antibody generation
- Prokaryotic expression systems
- Eukaryotic expression systems
- Tag-free protein purification methods